SCHEMBL31023792

SCHEMBL31023792

COc1ccc(C(c2ccc(OC)cc2)N2CCN(C(=O)n3nnc4cc(C#N)ccc43)CC2)cc1

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MGLL Q99685 7/20 0.53
▸ FAAH O00519 4/20 0.53
▸ CACNA2D1 P54289 4/20 0.43
▸ CACNB1 Q02641 4/20 0.43
▸ CACNA1B Q00975 3/20 0.43
▸ CACNA1C Q13936 2/20 0.43
▸ CACNA1G O43497 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ CYP19A1 P11511 1/20 0.40
▸ KMT2A Q03164 3/20 0.39
▸ MEN1 O00255 2/20 0.39
▸ CACNA1A O00555 1/20 0.38
▸ NPC1 O15118 1/20 0.38
▸ KDM4E B2RXH2 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ MAPT P10636 1/20 0.38
▸ HTT P42858 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31023817 0.96 MGLL (0.51) MGLLFAAHCACNA2D1CACNB1CACNA1B
SCHEMBL31023750 0.93 MGLL (0.53) MGLLFAAHCACNA2D1CACNB1CACNA1B
SCHEMBL31023864 0.92 MGLL (0.53) MGLLFAAHCACNA2D1CACNB1CACNA1B
SCHEMBL31023838 0.91 MGLL (0.60) MGLLFAAHKMT2AKDM4EMAPT
SCHEMBL31023930 0.91 MGLL (0.45) MGLLFAAHCACNA2D1CACNB1CACNA1B
SCHEMBL31023854 0.90 MGLL (0.53) MGLLFAAHCACNA2D1CACNB1CACNA1B
SCHEMBL31023735 0.89 MGLL (0.49) MGLLFAAHKDM4EALDH1A1
SCHEMBL31023739 0.87 MGLL (0.56) MGLLFAAHCACNA2D1CACNB1CACNA1B
SCHEMBL31023702 0.87 MGLL (0.48) MGLLFAAH
SCHEMBL31023684 0.83 MGLL (0.60) MGLLFAAHKMT2AKDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4665718-A1 SMALL MOLECULES AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS, COMPOSITIONS AND USE THEREOF Apogee Pharmaceuticals, Inc. (CA) 2025-12-24 — — EP disclosed
US-12378231-B2 Small molecules as monoacylglycerol lipase (MAGL) inhibitors, compositions and use thereof APOGEE PHARMACEUTICALS, INC. (CA) 2025-08-05 — — US disclosed
US-20240294514-A1 SMALL MOLECULES AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS, COMPOSITIONS AND USE THEREOF APOGEE PHARMACEUTICALS, INC. (CA) 2024-09-05 — — US disclosed
WO-2024168426-A1 SMALL MOLECULES AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS, COMPOSITIONS AND USE THEREOF APOGEE PHARMACEUTICALS, INC. (CA) 2024-08-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12378231-B2 Small molecules as monoacylglycerol lipase (MAGL) inhibitors, compositions and use thereof MGLL, PNLIP, LPL MGLL 1/4885FAAH 12/4885CACNA2D1 952/4885
US-20240294514-A1 SMALL MOLECULES AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS, COMPOSITIONS AND USE THEREOF MGLL, PNLIP, LPL MGLL 1/4885FAAH 12/4885CACNA2D1 952/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback